An Omniuous Sign for the Battle of Yacahn?

Author:
Updated:
Original:

Biogen Idec Inc. shareholders voted down Carl Icahn's proposed candidates for the board, according to initial counts by the company. Icahn, who felt that Biogen's attempt to sell itself last December was "flawed," wanted the biotechnology company to cut costs and improve research and employee morale.
Icahn found little support for his board, as major proxy adviser firms indicated that he had "failed to prove the sale process was mismanaged."
On a side (yet equally important) note, icahnreport.com seems to have "launched," though at present, the site is password protected. We look forward to hearing Icahn's thoughts on today's news.
--by Guest Carl Icahn lecturer Travis

Related